The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment

@article{Weiner2003TheL,
  title={The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment},
  author={Ina Weiner},
  journal={Psychopharmacology},
  year={2003},
  volume={169},
  pages={257-297}
}
  • I. Weiner
  • Published 25 February 2003
  • Psychology, Biology
  • Psychopharmacology
RationaleLatent inhibition (LI), namely, poorer performance on a learning task involving a previously pre-exposed non-reinforced stimulus, is disrupted in the rat by the dopamine (DA) releaser amphetamine which produces and exacerbates psychotic (positive) symptoms, and this is reversed by treatment with typical and atypical antipsychotic drugs (APDs) which on their own potentiate LI. These phenomena are paralleled by disrupted LI in normal amphetamine-treated humans, in high schizotypal humans… 
The relevance of irrelevance to schizophrenia
The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: Underpinned by the same process(es)?
TLDR
The theoretical and empirical analyses provide little support for a common process underlying deficits of latent inhibition in patients exhibiting positive symptoms of acute schizophrenia, and such deficits in experimental models in healthy humans and infrahumans.
Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia.
  • R. Lubow
  • Psychology, Medicine
    Schizophrenia bulletin
  • 2005
TLDR
Evidence to support both assumptions is presented, followed by a description of a conditioned attention theory that emphasizes the role of initial levels of attention elicited by repeated relevant and irrelevant stimuli, and the differences between these levels in schizophrenia and normal groups.
Disruption and Potentiation of Latent Inhibition by Risperidone: The Latent Inhibition Model of Atypical Antipsychotic Action
TLDR
It is concluded that atypical APDs exert in the LI model a dual pattern of effects, which enables detection of their ‘typical’ action (conditioning-based LI potentiation) as well as a dissociation from typical APDs by their “atypical” action (pre-exposure- based LI disruption).
Latent inhibition as a model of schizophrenia: from learning to psychopathology
In schizophrenia, attentional processes may be altered and become the basis of another symptomatology such as delirium and hallucinations. One of the experimental approaches to the study of
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia
TLDR
The results point to functionality within brain systems regulating LI acquisition but not those regulating LI expression in periadolescent rats, further suggesting that postpubertal maturation of the latter systems may underlie schizophrenia-mimicking LI disruption reported in adult rats following perinatal manipulations and possibly disrupted LI observed in schizophrenia.
Towards an animal model of an antipsychotic drug-resistant cognitive impairment in schizophrenia: scopolamine induces abnormally persistent latent inhibition, which can be reversed by cognitive enhancers but not by antipsychotic drugs.
  • S. Barak, I. Weiner
  • Psychology, Medicine
    The international journal of neuropsychopharmacology
  • 2009
TLDR
Scopolamine-induced persistent LI may provide a pharmacological LI model for screening cognitive enhancers that are efficient for the treatment of APD-resistant cognitive impairments in schizophrenia.
The amphetamine-induced sensitized state as a model of schizophrenia
Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol
TLDR
MK-801-induced perseveration of LI is consistent with other reports of perseverative behaviors, suggested to be particularly relevant to negative symptoms of schizophrenia, following NMDA receptor blockade, and the model may provide a unique screening tool for the identification of novel antipsychotic compounds.
...
...

References

SHOWING 1-10 OF 499 REFERENCES
The latent inhibition model of schizophrenia: Further validation using the atypical neuroleptic, clozapine
The pharmacology of latent inhibition as an animal model of schizophrenia
Clinical features of latent inhibition in schizophrenia
The differential effects of chlorpromazine and haloperidol on latent inhibition in healthy volunteers
TLDR
The effect of antipsychotic drug effects on auditory LI is both modality and pharmacologically dependent and that further research using a wider range of antippsychotic compounds is necessary to clarify the cognitive effects of these drugs, and to determine whether there are important differences between them.
Associative deficit accounts of disrupted latent inhibition and blocking in schizophrenia
Disrupted and Undisruptable Latent Inhibition following Shell and Core Lesions
TLDR
The switching model of LI proposed that the switching mechanism of the NAC resides in the core and that the switched mechanism is inhibited by the shell, which implies that it should be impossible to disrupt LI in rats with a core lesion and leads to the counterintuitive prediction that a lesion that destroyed both shell and core would leave LI intact.
From an animal model of an attentional deficit towards new insights into the pathophysiology of schizophrenia.
Disruption and Potentiation of Latent Inhibition by Risperidone: The Latent Inhibition Model of Atypical Antipsychotic Action
TLDR
It is concluded that atypical APDs exert in the LI model a dual pattern of effects, which enables detection of their ‘typical’ action (conditioning-based LI potentiation) as well as a dissociation from typical APDs by their “atypical” action (pre-exposure- based LI disruption).
The Latent Inhibition Model of Schizophrenia
TLDR
The results of these lines of LI research have now converged to provide interesting leads on the neuropsychology and pathophysiology of schizophrenia, at present largely speculative, but ripe to be tested in the clinic.
A simple (or simplistic?) cognitive model for schizophrenia.
  • D. Hemsley
  • Psychology, Medicine
    Behaviour research and therapy
  • 1993
...
...